Tesamorelin Results Timeline

Tesamorelin's approved use is HIV lipodystrophy

Tesamorelin is a growth-hormone-releasing hormone analog with FDA labeling for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That is the context for the core clinical evidence.

A page about results should say this before discussing timelines. A claim about general weight loss, aging, or cosmetic body recomposition needs direct evidence in that population, not a borrowed HIV-lipodystrophy result.

What the trials measured at six months

In a 26-week randomized trial, adults with HIV and abdominal fat accumulation were assessed with CT-based visceral adipose tissue outcomes. Another 6-month trial evaluated visceral and liver fat in a defined HIV population.

These are objective endpoints, but they are still specific to the study setting. They do not tell a reader what their mirror, scale, or waist will show on a particular date.

What happened with continued treatment and withdrawal

A 12-month randomized safety-extension study reported further visceral-fat reduction among participants who continued tesamorelin. Participants who switched from tesamorelin to placebo rapidly lost the initial improvement.

This is a useful expectation-setting result. It shows that a short-course before-and-after story is incomplete and that discontinuation changed the measured outcome in this study.

Visceral fat is not every outcome

The trials measured visceral adipose tissue and related metabolic or imaging outcomes. They did not establish a universal claim about appearance, athletic performance, energy, or long-term health for people outside the study population.

Even within HIV-associated lipodystrophy, a reader should distinguish a measured imaging outcome from an individual experience or a promise of lasting health benefit.

Safety and monitoring remain clinical

The FDA label includes warnings, contraindications, and monitoring considerations that belong with the labeled product and a prescriber's evaluation. This article should point readers to the label and clinician, not recite a consumer dosing program.

Claims about compounded tesamorelin need an additional boundary. A provider-listed compounded product is not automatically the FDA-approved product studied in the label and trials.

How to read a provider timeline claim

Ask whether the claim names the studied population, the endpoint, and the time frame. If it turns a CT-based HIV-lipodystrophy result into a universal promise of rapid fat loss, it goes beyond the evidence.

Provider prices and availability can change, but they do not change the clinical boundary. A live listing belongs after the evidence conclusion, not inside it.

Do not use trial schedules as injection instructions or combine tesamorelin with other products from an editorial timeline.

The clearest result is a CT-measured visceral-fat change at six months

In the 12-month extension study, participants continuing tesamorelin had a 10.9% reduction in visceral adipose tissue at six months, compared with a 0.6% increase with placebo. This is the concrete result behind many tesamorelin timeline claims, and it belongs to adults with HIV-associated lipodystrophy in that trial context.

The statistic is useful precisely because it is specific. It is a CT-based visceral-fat result, not a projection about scale weight, mirror changes, general obesity, athletic performance, or a cosmetic-body-recomposition timeline. It helps readers identify the endpoint that was actually measured instead of reading a broad body-change claim into a single trial number.

Stopping treatment changed the measured outcome

The same extension study reported that participants switched from tesamorelin to placebo rapidly lost the initial visceral-fat improvement. This makes a short before-and-after story incomplete: continued treatment and withdrawal mattered in the trial.

That is an important expectation-setting fact, but it still does not establish indefinite benefit or predict a personal result. The outcome remains tied to the labeled HIV-lipodystrophy population and the trial's imaging endpoint.

Read a provider result claim against the FDA indication

EGRIFTA SV is labeled for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A provider advertising tesamorelin should state whether its claim matches that indication, the studied population, and the measured endpoint.

A compounded listing is not automatically the FDA-labeled product studied in the trials. The product, route, eligibility, and monitoring plan should be discussed directly with the treating clinician rather than inferred from a timeline article.